Compare Eli Lilly And Co (LLY) vs United States Natural Gas Fund (UNG) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

UNG trades at $10.29, down 2.09% in the last session, with technical indicators signaling a bearish trend. The stock shows oversold conditions on short-term RSI readings but faces strong selling pressure from moving averages. Recent news highlights volatility in natural gas futures, with prices influenced by weather forecasts and LNG demand fluctuations. Fundamental data is unavailable, limiting traditional valuation analysis.

The outlook remains cautious due to commodity price dependency and lack of fundamental metrics. Risks include energy market volatility and competition from equity-based natural gas ETFs. Analyst sentiment is mixed, with technicals leaning bearish but potential for short-term rebounds if gas prices stabilize.